Citigroup Inc Summit Therapeutics Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Citigroup Inc holds 63,575 shares of SMMT stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,575

Previous 559,006 88.63%

Holding current value

$1.39 Million

Previous $2.31 Million 78.61%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.39 - $10.92 $1.18 Million - $5.41 Million	-495,431 Reduced 88.63%	63,575 $495,000
Q1 2024 May 10, 2024	BUY	$2.55 - $5.07 $1.35 Million - $2.69 Million	529,869 Added 1818.54%	559,006 $2.31 Million
Q4 2023 Feb 09, 2024	BUY	$1.67 - $2.83 $33,531 - $56,823	20,079 Added 221.67%	29,137 $76,000
Q3 2023 Nov 09, 2023	SELL	$1.54 - $2.42 $62,810 - $98,702	-40,786 Reduced 81.83%	9,058 $16,000
Q2 2023 Aug 10, 2023	SELL	$1.32 - $2.81 $13,368 - $28,459	-10,128 Reduced 16.89%	49,844 $125,000
Q1 2023 May 11, 2023	BUY	$1.38 - $5.41 $6,378 - $25,005	4,622 Added 8.35%	59,972 $104,000
Q4 2022 Feb 09, 2023	BUY	$0.68 - $5.31 $35,904 - $280,373	52,801 Added 2071.44%	55,350 $235,000
Q3 2022 Nov 10, 2022	BUY	$0.89 - $1.63 $737 - $1,351	829 Added 48.2%	2,549 $3,000
Q2 2022 Aug 10, 2022	SELL	$0.92 - $2.38 $1,444 - $3,736	-1,570 Reduced 47.72%	1,720 $2,000
Q1 2022 May 12, 2022	SELL	$2.0 - $3.45 $14,424 - $24,881	-7,212 Reduced 68.67%	3,290 $8,000
Q4 2021 Feb 10, 2022	BUY	$2.45 - $5.64 $3,692 - $8,499	1,507 Added 16.75%	10,502 $28,000
Q3 2021 Nov 10, 2021	BUY	$4.83 - $8.27 $43,445 - $74,388	8,995 New	8,995 $45,000

Others Institutions Holding SMMT

# of Institutions

138

Shares Held

64.4M

Call Options Held

1.06M

Put Options Held

1.02M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.41B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account